| Vol. 15.22 – 16 June, 2023 |
| |
|
|
| Enterocloster species that recolonized the guts of mice treated with antibiotics down-regulated the expression of MAdCAM-1, the ligand for integrin α4β7 that helps to retain an immunosuppressive subset of T cells within the gut. [Science] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Mice with a homologous mutation exhibited hyperinflammation and greater susceptibility to collagen antibody-induced arthritis, accompanied with pathological osteoclastogenesis. Scientists leveraged this to design an IL-1 therapeutic, which trapped IL-1β and IL-1α, but not IL-1Ra. [Immunity] |
|
|
|
| The authors identified a subpopulation of CD146+ tumor-associated macrophages that exerted antitumor activity in both human samples and animal models. [Cellular & Molecular Immunology] |
|
|
|
| Researchers demonstrated, using a combination of single cell and spatial RNA sequencing, IL-36 dependent amplification of IL-17A and TNF inflammatory responses in the absence of neutrophil proteases, which primarily occurred within the supraspinous layer of the psoriatic epidermis. [Nature Communications] |
|
|
|
| Administration of a function-blocking antibody against CD8α effectively prevented disease onset, reduced morbidity and mortality, and prevented central nervous system demyelination in mice. [Journal Of Experimental Medicine] |
|
|
|
| Tolerogenic microparticles were validated in vitro and then evaluated in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis. [Science Advances] |
|
|
|
| Scientists showed that the administration of exogenous mouse major histocompatibility complex class II protein bounding a unique galactosylated collagen type II peptide directly interacted with the antigen-specific T cell receptor through a positively charged tag. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers used CD4+ T cells expressing a transgenic T cell receptor specific for desmoglein 3, which is the target antigen of the autoimmune bullous disease pemphigus vulgaris, to examine how peripheral immunological tolerance against pathogenic autoreactive CD4+ T cells changed with age. [Immunity & Ageing] |
|
|
|
| Oral administration of acyl-CoA synthetase-1 (ACSL1) inhibitor triacsin-C in mice before acute-high-fat feeding normalized the inflammatory/foamy phenotype of the circulatory monocytes by suppressing FABP4 expression. [iScience] |
|
|
|
|
| Scientists review new information that has appeared in recent years on the diversity of Tregs, the importance of the transcription factor FOXP3, how T cell receptors influence their fate, and the unexpected and varied cellular partners that influence Treg cell homeostatic setpoints. [Nature Reviews Immunology] |
|
|
|
| The authors review the evidence describing key cellular networks within and between the liver, gastrointestinal tract, and adipose tissue that control systemic metabolism and how these cell circuits become dysregulated during certain metabolic diseases. [Immunity] |
|
|
|
|
| Mozart is developing a portfolio of CD8 Treg Modulators including MTX-101, a bispecifc autoimmune checkpoint inhibitor, for the treatment of autoimmune diseases. The company anticipates filing an investigational new drug and initiating a Phase I clinical trial for MTX-101 in early 2024. [Mozart Therapeutics] |
|
|
|
|
| July 2 – 7, 2023 Vaud, Switzerland |
|
|
|
|
|
| King’s College London – London, England, United Kingdom |
|
|
|
| Karolinska Institutet – Solna, Sweden |
|
|
|
| BioMed X – Ridgefield, Connecticut, United States |
|
|
|
| Karolinska Institutet – Solna, Sweden |
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
|